Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
BD Medical Segment Transforming to deliver higher impact solutions Tom Polen EVP and President, BD Medical Segment © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. BD MEDICAL IS TRANSFORMING TO HIGHER IMPACT SOLUTIONS AND GROWTH. © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Significant progress executing our Medical strategy over the last five years Medical Five years ago our journey began Factors BD response Global diabetes challenging • Accelerate first-to-market innovation: differentiate pen needles and enter insulin infusion • Continue opportunity sensing Cancer therapies expanding rapidly • Acquire Carmel Pharma • Accelerate market development in U.S., Europe and Japan Chronic disease proliferating globally • Focused platform initiative including autoinjectors and other new products • Big Pharma partner model © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Key strategic areas FY 2016 revenues Leadership position FY 2019 Segment size Market growth MPS • • • • • PIVC1 Hypodermic Flush Skin antisepsis IV connectors / sets $3.4B #1 $15.5B 3% to 4% MMS • • • Infusion Dispensing Retail2 $2.2B #1 $9.0B 3% to 4% DC • • Core injection Insulin infusion $1.0B #1 $2.5B 4% to 5% PS BD Medical is $7.8B in sales and is the leader in each of four businesses • • • Prefilled (PFS) Safety SAIS3 $1.2B #1 $2.6B 4% to 5% 1. 2. 3. PIVC: Peripheral intravenous catheter Retail market growth rate = ~10% Self administered injection systems (SAIS ) market growth rate = ~15% © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Healthcare is being actively reshaped Process management Changes in payer models Driving an increased focus on outcomes Catalyzing change for our customers Decentralization of care Digital health and smart devices Holistic disease management © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Healthcare is being actively reshaped “ I need to think about getting better processes, not just better products. ” - Nurse Changes in payer models Driving an Driving an increased increased focuson on focus outcomes outcomes Catalyzing change for our customers © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Healthcare is being actively reshaped “ My outpatient volumes are growing 3x more than inpatient. ” - Doctor Changes in payer models Driving an increased focus on outcomes Catalyzing change for our customers © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Healthcare is being actively reshaped “ Managing my disease can be easier using digital technology. ” - Patient Changes in payer models Driving an increased focus on outcomes Catalyzing change for our customers © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Healthcare is being actively reshaped “ We’re changing payment systems to reimburse wellness, not just sickness. ” - Payer Changes in payer models Driving an increased focus on outcomes Catalyzing change for our customers © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. And BD is transforming the Medical Segment to deliver solutions for these opportunities ++ Care continuum + Med mgmt + Patient safety Served markets Less complex med devices • Sales: $4.5B + Informatics • Sales: $7.8B ++ Disease management ++ Digital health • Solutions provider • New capability builds • Refine the portfolio in areas to win $14B © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. $30B Our journey ahead is focused on four strategic pillars 1 Re-invent the medication management process across the care continuum 2 Prevent infections and improve safety for healthcare workers © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. 3 Advance the treatment of diabetes and other chronic diseases 4 Expand globally New product pipeline will continue to fuel our growth Med management FY 2017 Chronic disease Infection prevention and HWS BD Intelliport™ Smart CUBIE Pyxis™ Mini ChloraShield™ catheter dressings BD Cathena™ FY 2018 Med View Dashboard Pharmogistics™ Vmax / CMax Next-gen ChloraPrep™ Pyxis™ ES Enhancements Hazardous drug detection Integrated BD Cato™ FY 2019* U.S. Retail New markets infection prevention Rowa™ Dose Next-gen BD PhaSeal™ * BD Neopak™ BD UltraSafe Plus™ line extensions line extensions BD Hylok™ BD FlowSmart™ © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Smart pen needles T2 Patch wearable injector BD Intevia™ next-gen (AI) BD Libertas™ wearable injector Re-inventing medication management across the care continuum direct medical costs incurred due to medication errors $600K in annual waste per hospital 3X growth of outpatient vs inpatient volumes © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Medication Management Solutions Reinventing medication management across the care continuum Ranjeet Banerjee WW President, Medication Management Solutions Tom Utech VP, Solution Management and Marketing, Medication Management Solutions © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. OUR STRATEGY TO REINVENT MEDICATION MANAGEMENT ACROSS THE CONTINUUM WILL CREATE SUBSTANTIAL VALUE FOR OUR CUSTOMERS. © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Medication errors are a substantial cause of death, source of misuse and costly burden Medical errors are the third leading cause of death Medication errors represent one-third of all medical errors Impact on patients medication errors each year U.S. patient injuries annually © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Impact on systems direct medical costs in U.S. due to medication errors average annual waste in large hospitals Current medication management trends present a significant opportunity “It’s challenging to balance operational activities and increasing clinical needs.” - Pharmacist Increasing acuity of patients and complex medication regimens “I’m facing tighter cost, quality and regulatory pressures.” - CFO Tightening healthcare budgets and focus on decreasing costs and improving outcomes © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. “I don’t have the patient information I need when I need it.” - Nurse Broadening continuum of care and discontinuity in information BD is #1 in the acute segment and uniquely positioned to create value across the med management process Hosted device data Pharmacy Pharmogistics™ BD Cato™ >500 Pharmogistics™ / BD Cato™ sites Floor ES Link Pyxis™ >7,500 Pyxis™ customers globally HIT connectivity engine © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Patient care Alaris™ Alaris™ interoperability 1.5M+ Alaris™ channels installed The hosted environment not only collects end-to-end data within a facility, but across the enterprise Device data collected across health systems… Hosted device data …provides foundation for new capabilities National benchmarking 3000+ U.S. acute hospitals Process improvements Analytics © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Focusing on three strategies to drive growth and reinvent medication management Addressable opportunity Advance our “best-in-category” product lead $2B Unlock new value through end-toend informatics Expand across the care continuum © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. $1B Video to be inserted: 8252MMSEfficiencyAnalystVideoD17227.mov Advancing our best-in-category products’ lead with an increased innovation cadence Infusion Dispensing FY 2017 Enterprise Smart CUBIE system Enterprise Pharmogistics™ Enterprise-wide secure transportation and tracking Enterprise-wide perpetual inventory management FY 2018 Integrated BD Cato™ End-to-end interoperability and integrated workflows Pyxis MedStation™ Next-gen controlled enhancement substance Software and hardware enhancements Next-gen software and configurable storage Alaris™ clinical enhancements BD Intelliport™ Alaris™ next-gen connectivity PCA interoperability Next-gen platform Improved drug library and alarm features Informatics-enabled IV bolus injections New informatics capabilities Bi-directional patient controlled analgesia Leapfrog clinical safety, informatics and interoperable platform © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Information integration can eliminate gaps in the system, creating new value Waste Cost 5%–6% 20% of meds stocked in cabinets have of pharmacy budgets consumed by inventory waste not been accessed in 6 months X X Inventory management IV compounding X Infusion pump Automated dispensing cabinet Safety 9% of preps made using “pull back” check method contain errors © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. X Safety 67% of IVs have one or more errors Video to be inserted 8253MMSShortEditR3h264p.mov Integrating BD products and processes to unlock new value through end-to-end informatics Hosted device data ✓ ✓ ✓ ✓ Informatics capabilities Workflow interoperability Optimization analytics National benchmarking Within a single facility System-level optimization Across peer health systems FY 2017 © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. FY 2018 Building on our leadership in acute care, we are expanding our presence across the care continuum… Patients are increasingly seeking care outside of the hospital… …creating opportunities to serve these expanding markets Devices TECH FY 2017 FY 2018+ ES enterprise server ES deployment enterprise-wide MMS cloud Simplifies non-acute product deployment Pyxis™ Mini ROWA™ dose Ambulatory infusion Non-acute medication management High-volume patient dose packaging Explore growing segment © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. …including transforming the retail pharmacy Today Inventory waste Future Efficient inventory management Vmax Patient purchase confusion Improved patient experience Long wait times Increased access © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Vmotion Vis-a-via BD is #1 in the retail segment and will expand our portfolio to pursue new opportunities ROWA™ Vmax 210 Core market Our development plan expands the addressable market by 2 times Higher storage capacity ROWA™ Cmax Geographic expansion to China Channel system for rapid dispensing 2021+ 2018 >6,000 EU Vmax / Vmotion customers installed Region-specific transformation and new market entry 2017 Vis-a-via 2016 © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. After-hours prescription pickup OUR STRATEGY TO REINVENT MEDICATION MANAGEMENT ACROSS THE CONTINUUM WILL CREATE SUBSTANTIAL VALUE FOR OUR CUSTOMERS. © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. IN ADVANCING SAFETY FOR PATIENTS AND HEALTHCARE WORKERS THROUGHOUT THE WORLD. © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Safety and healthcare-associated infections continue to be substantial issues U.S. cost of healthcare-associated infections 1 in 15 patients acquire infection during care Accidental needlesticks remain a significant issue © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Continuing our global momentum in creating a safer environment for healthcare workers Total global conversion to safety is 34% today Expanding our hazardous drug safety portfolio Safety IV catheter and syringe global penetration Current segment size = $200M growing >10% (16% penetration) 84% U.S. 54% E.U. 19% China BD PhaSeal™ Leveraging BD DS capabilities to advance the market into hazardous drug safety <11% emerging markets BD is continuing our drive to conversions, with focus on E.U. and emerging markets © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Segment potential = $1.3B Hazardous drug detection (FY18) Patient safety and infection prevention has become a core franchise for BD globally Past Today Legacy BD Legacy CFN New BD Primarily vascular IP Primarily surgical IP Patient safety and infection prevention leader Revenue ~$500M ~$450M ~$950M Served segments $800M $1.0B $1.8B Scope Global Primarily U.S. Global Clinical area © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Chloraprep video Attacking a global problem through market development and expansion U.S. E.U. China ROW 2% 3.5% 4.7% 5.6% 67% 10% 0% 4% Sustain Expand Develop Develop Surgical ChloraPrep™ example Surgical site infection rates ChloraPrep™ penetration ChloraPrep™ growth strategy Innovation and market expansion © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Registration and market development Investing in innovation across the patient safety and infection prevention landscape Development plan ChloraPrep™, BD PosiFlush™, MaxPlus™, Integrated catheters 2021+ 2017 2016 ChloraShield™ catheter dressings © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. + ~1 new launch / year Expanding addressable market by 3x by 2021 BD IS ENABLING SAFER AND MORE CONVENIENT DELIVERY OF BIOLOGICS. © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. BD is advancing the treatment of chronic disease through partnerships with pharma Portfolio BD Neopak™ Strengthening our leading position while… BD Hylok™ BD Sterifill Advance™ 4 out of 5 PFS biologics delivered using a BD device today Line extensions (XSi™, Durashield™) Line extensions FY17–18 FY17-FY18 BD Physioject™ autoinjector (AI) …creating new growth vectors in SAIS BD UltraSafe Plus™ 10% share $700M segment >15% growth © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. BD Vystra™ variable dose pen FY18 FY17–18 BD Intevia™ BD Libertas™ next-gen (AI) wearable injector Today FY16 FY18 FY19 Rheumatoid arthritis, MS Diabetes, fertility, growth Highviscosity drugs Long-duration viscous biologics And investing to directly improve the lives of patients with diabetes direct medical costs from diabetes worldwide ~415M patients with diabetes worldwide in 2015 >60% diabetics using insulin without glycemic control © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Diabetes Care Simplifying diabetes management Ken Miller Worldwide President BD Medical-Diabetes Care WE ARE UNIQUELY POSITIONED TO DELIVER THE DIABETES SOLUTIONS FOR TOMORROW © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Leveraging our strengths to deliver transformative innovation and growth Commitment to diabetes innovations and data generation Expanding served markets by 2x by 2021 Scale and reach in over 80 countries 2021+ 2017 Build upon leadership in retail channel Launch BD FlowSmart™ 2016 Consistent first-in-class portfolio innovations Injection Diabetes is a global epidemic Today’s impact 2040 impact A person with diabetes dies every 7 seconds Deliver solutions of tomorrow 1 Lead in injection 2 Expand drug delivery portfolio 3 Deliver transformative solutions 1924 to today Patients served Lead in injection History of firsts has revolutionized drug delivery © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. We will continue our commitment to innovating in injection By delivering patient-centered solutions through a cadence of innovation comfort safety simplicity affordability New product launch every year for next five years © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Satisfying significant unmet needs with BD FlowSmart™ technology Expand drug delivery portfolio • Developed in partnership with JDRF and The Helmsley Charitable Trust • Commercializing in partnership with Medtronic • Limited launch underway 77% decrease in flow interruptions Full-scale global launch begins Q2 FY 17 © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Our leadership position enables delivery of transformative innovations We touch million patients … by building upon Our commitment Our scale and reach Our innovations Patient Video The burden is REAL TRANSFORMING DIABETES CARE From drug delivery devices to leadership in interconnected diabetes management solutions BD uniquely positioned to deliver transformative solutions To serve … addressing unmet needs Embarrassment Complexity Confusion million patients >60% Patients are not in glucose control An elegant solution to simplify the lives of type 2 patients Deliver transformative solutions Intuitive design Adjustable basal and bolus Affordable pricing Emerging billion-dollar product category © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Anelegant elegantsolution solutionto tosimplify simplifythe thelives livesof of An Type22patients patients type Deliver transformative solutions Intuitive design Emerging 54 billion-dollar product category © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Anelegant elegantsolution solutionto tosimplify simplifythe thelives livesof of An Type22patients patients type Deliver transformative solutions Intuitive design Adjustable basal and bolus Emerging billion-dollar product category Anelegant elegantsolution solutionto tosimplify simplifythe thelives livesof of An Type22patients patients type Deliver transformative solutions Intuitive design Adjustable basal and bolus Affordable pricing Emerging 56 billion-dollar product category © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. An elegant solution to simplify the lives of type 2 patients Deliver transformative solutions Intuitive design Adjustable basal and bolus Affordable pricing Emerging billion-dollar product category © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. An interconnected solution for a population of type 2 patients Deliver transformative solutions © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. An interconnected solution for a population of type 2 patients Deliver transformative solutions • Irrefutable dose data enabled by wireless connectivity © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. An interconnected solution for a population of type 2 patients Deliver transformative solutions • Irrefutable dose data enabled by wireless connectivity • Dose data seamlessly combined with glucose, diet and activity data © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. An interconnected solution for a population of type 2 patients Deliver transformative solutions • Irrefutable dose data enabled by wireless connectivity • Dose data seamlessly combined with glucose, diet and activity data • Generation of insights to improve care • Benefits for patients, caregivers, HCPs, payers © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Despite advances interconnected diabetes management remains out of reach for many Making IDM accessible for all diabetes injectors with BD smart pen needle technology Deliver transformative solutions © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Making IDM accessible for all diabetes injectors with BD smart pen needle technology Deliver transformative solutions • Designed to capture irrefutable dose data © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Making IDM accessible for all diabetes injectors with BD smart pen needle technology Deliver transformative solutions • Designed to capture irrefutable dose data • Wireless communication of dose data to integrate with other data © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Making IDM accessible for all diabetes injectors with BD smart pen needle technology Deliver transformative solutions • Designed to capture irrefutable dose data • Wireless communication of dose data to integrate with other data • Universal fit with all disposable insulin pens © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Making IDM accessible for all diabetes injectors with BD smart pen needle technology Deliver transformative solutions • Designed to capture irrefutable dose data • Wireless communication of dose data to integrate with other data • Universal fit with all disposable insulin pens • Affordable pricing © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Leverage BD scale, reach and capabilities to bring benefits of IDM to the world TODAY WITH BD TRANSFORMATIVE SOLUTIONS We are uniquely positioned to deliver the solutions of tomorrow Products solutions 1 Lead in injection 2021+ 2018 2 2017 Expand drug delivery portfolio 2016 3 Deliver transformative solutions Launch BD FlowSmart™ Injection Launch patch pump and smart pen needle Expanding served markets by 2x WE ARE UNIQUELY POSITIONED TO DELIVER THE DIABETES SOLUTIONS FOR TOMORROW © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Increased relevance of informatics to focus on customer outcomes and connectivity Current portfolio Building new capabilities Technology solutions Pharmogistics™ MedMined™ • Interoperability • Smart devices • Digital health offerings BD Cato™ Interoperability $200M+ in revenue Future portfolio Core BU New digital health BU >450 employees in technology solutions © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. Revenue synergies will bring combined BD Medical + CFN towards 5% top line growth Register and customize Register existing products internationally Target ~200 Local customization Examples: Rowa™ Cmax 142* Develop markets Drive market development and adoption • Near-term: Focus on adoption • Mid- / long-term: Drive market development IV sets Existing products to new markets through Q3 2017 *Registered or in process through Q42016 © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. And BD is transforming the Medical Segment to deliver solutions for these opportunities ++ Care continuum + Med mgmt + Patient safety Served markets Less complex med devices • Sales: $4.5B + Informatics • Sales: $7.8B ++ Disease management ++ Digital health • Solutions provider • New capability builds • Refine the portfolio in areas to win $14B © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. $30B BD MEDICAL IS TRANSFORMING TO HIGHER IMPACT SOLUTIONS AND GROWTH. © 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.